UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

### NOTICE OF ALLOWANCE AND FEE(S) DUE

101325 7590 03/08/2016 GLOBAL PATENT GROUP - HOR 1005 NORTH WARSON ROAD SUITE 404 SAINT LOUIS, MO 63132 EXAMINER RAO, SAVITHA M

ART UNIT PAPER NUMBER
1621

DATE MAILED: 03/08/2016

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/958,259	12/03/2015	Bruce Scharschmidt	HOR0026-201TC2-US	3046

TITLE OF INVENTION: METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	06/08/2016

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN <u>THREE MONTHS</u> FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. <u>THIS STATUTORY PERIOD CANNOT BE EXTENDED</u>. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

### HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

Find authenticated court documents without watermarks at docketalarm.com.

### PART B - FEE(S) TRANSMITTAL

### Complete and send this form, together with applicable fee(s), to: <u>Mail</u> Mail Stop ISSUE FEE **Commissioner for Patents** P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

101325 7590 03/08/2016 **GLOBAL PATENT GROUP - HOR** 1005 NORTH WARSON ROAD SUITE 404 SAINT LOUIS, MO 63132

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

**Certificate of Mailing or Transmission** I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/958,259 ITLE OF INVENTION	12/03/2015	VELITIC MONITORI	Bruce Scharschmidt NG OF NITROGEN SCAVI	ENGING DRUGS	HOR0026-201TC2-US	3046
	. METHODS OF THER		NO OF MIROOLEN SCAVI	ENGING DRUGS		
APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE	FEE TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	06/08/2016
EXAN	IINER	ART UNIT	CLASS-SUBCLASS	l		
	VITHA M	1621	424-009200			
Change of correspond	ence address or indicatior	of "Fee Address" (37	2. For printing on the p			
FR 1.363).	ondence address (or Chai	nge of Correspondence	(1) The names of up to or agents OR, alternativ			
<ul> <li>Change of correspondence address (or Change of Corresponde Address form PTO/SB/122) attached.</li> <li>"Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Custon Number is required.</li> </ul>			(2) The name of a singl registered attorney or a 2 registered patent attor listed, no name will be	e firm (having as a r gent) and the names rneys or agents. If no printed.	s of up to	
PTO/SB/47; Rev 03-0 Number is required	•		TTHE DATENTS (	e)		
Number is required	ND RESIDENCE DATA	TO BE PRINTED ON	THE PATENT (print or typ			
Number is required ASSIGNEE NAME A	ND RESIDENCE DATA		e data will appear on the pa OT a substitute for filing an	atent. If an assigned assignment.	e is identified below, the d	ocument has been filed
Number is required ASSIGNEE NAME A	ND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp					ocument has been filed
Number is required ASSIGNEE NAME A PLEASE NOTE: Un recordation as set for (A) NAME OF ASSI lease check the appropri- a. The following fee(s) Issue Fee Publication Fee (f	ND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp GNEE riate assignee category or	fied below, no assigne letion of this form is No categories (will not be ermitted)	e data will appear on the pa OT a substitute for filing and (B) RESIDENCE: (CITY printed on the patent) : 4b. Payment of Fee(s): ( <b>Plea</b> A check is enclosed. Payment by credit car	and STATE OR CO Individual Cor se first reapply any d. Form PTO-2038 i	DUNTRY) poration or other private gro previously paid issue fee s attached.	oup entity 🔲 Governm shown above)
Number is required. ASSIGNEE NAME A PLEASE NOTE: Un recordation as set fori (A) NAME OF ASSI lease check the appropria. The following fee(s) Issue Fee Publication Fee (1) Advance Order - 4	ND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp GNEE riate assignee category or are submitted: No small entity discount p # of Copies	fied below, no assigne letion of this form is No categories (will not be ermitted)	e data will appear on the pa OT a substitute for filing and (B) RESIDENCE: (CITY printed on the patent) : 4b. Payment of Fee(s): ( <b>Plea</b> A check is enclosed. Payment by credit car	and STATE OR CO Individual Cor se first reapply any d. Form PTO-2038 i	DUNTRY) poration or other private gro previously paid issue fee	oup entity 🔲 Governm shown above)
Number is required. ASSIGNEE NAME A PLEASE NOTE: Un recordation as set fort (A) NAME OF ASSI lease check the appropri- a. The following fee(s) Issue Fee Publication Fee (1) Advance Order - 4 . Change in Entity Sta	ND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp GNEE riate assignee category or are submitted: No small entity discount p	fied below, no assigne letion of this form is No categories (will not be ermitted)	e data will appear on the pa OT a substitute for filing and (B) RESIDENCE: (CITY printed on the patent) : 4b. Payment of Fee(s): (Pleat A check is enclosed. Payment by credit car The director is hereby overpayment, to Depo	and STATE OR CO Individual Cor se first reapply any d. Form PTO-2038 i authorized to charge sit Account Number	DUNTRY) poration or other private gro previously paid issue fee s attached. the required fee(s), any def	bup entity Governm shown above) icciency, or credits any n extra copy of this form
Number is required. ASSIGNEE NAME A PLEASE NOTE: Un recordation as set fori (A) NAME OF ASSI lease check the appropriate of the following fee(s) a. The following fee(s) Issue Fee Publication Fee (1) Advance Order - 4 . Change in Entity Sta	IND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp GNEE iate assignee category or are submitted: No small entity discount p # of Copies tus (from status indicated	fied below, no assigne letion of this form is No categories (will not be ermitted)  above) e 37 CFR 1.29	<ul> <li>e data will appear on the part of a substitute for filing and (B) RESIDENCE: (CITY</li> <li>printed on the patent):</li> <li>4b. Payment of Fee(s): (Plean A check is enclosed.</li> <li>Payment by credit car</li> <li>The director is hereby overpayment, to Depoor</li> <li><u>NOTE:</u> Absent a valid cere fee payment in the micro</li> </ul>	and STATE OR CO Individual Cor se first reapply any d. Form PTO-2038 i authorized to charge sit Account Number rtification of Micro I entity amount will n	DUNTRY) poration or other private gro previously paid issue fee s attached. the required fee(s), any det	bup entity Governm shown above) Ticiency, or credits any n extra copy of this form D/SB/15A and 15B), issu
Number is required. ASSIGNEE NAME A PLEASE NOTE: Un recordation as set for (A) NAME OF ASSI lease check the appropu a. The following fee(s) Issue Fee Publication Fee (1 Advance Order - 4 . Change in Entity Sta Applicant assertin —	IND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp GNEE riate assignee category or are submitted: No small entity discount p # of Copies tus (from status indicated ng micro entity status. Sec	fied below, no assigne letion of this form is No categories (will not be ermitted) above) above) 37 CFR 1.29 37 CFR 1.27	<ul> <li>e data will appear on the partial of a substitute for filing an (B) RESIDENCE: (CITY</li> <li>printed on the patent) :</li> <li>4b. Payment of Fee(s): (Plea</li> <li>A check is enclosed.</li> <li>Payment by credit car</li> <li>The director is hereby overpayment, to Depo</li> <li><u>NOTE:</u> Absent a valid cet fee payment in the micro</li> <li><u>NOTE:</u> If the application to be a notification of loss</li> </ul>	and STATE OR CO Individual Cor se first reapply any d. Form PTO-2038 i authorized to charge sit Account Number rtification of Micro I entity amount will n was previously unde s of entitlement to m	DUNTRY) poration or other private gro previously paid issue fee s attached. the required fee(s), any def	bup entity Governm shown above) Ticiency, or credits any n extra copy of this form D/SB/15A and 15B), issu application abandonmenting this box will be taken
Number is required. ASSIGNEE NAME A PLEASE NOTE: Un recordation as set for (A) NAME OF ASSI lease check the appropu a. The following fee(s) Issue Fee Publication Fee (1 Advance Order - 4 . Change in Entity Sta Applicant certifyi Applicant changin	IND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp GNEE riate assignee category or are submitted: No small entity discount p \$ of Copies	fied below, no assigne letion of this form is No categories (will not be ermitted) above) 2 37 CFR 1.29 37 CFR 1.27 fee status.	<ul> <li>e data will appear on the particle of the particle of</li></ul>	and STATE OR CO Individual Cor se first reapply any d. Form PTO-2038 i authorized to charge sit Account Number rtification of Micro I entity amount will n was previously unde of entitlement to m a will be taken to be	DUNTRY)         poration or other private growth         y previously paid issue feet         s attached.         e the required fee(s), any defect	bup entity Governm shown above) Ticiency, or credits any n extra copy of this form D/SB/15A and 15B), issu application abandonmenting this box will be taken
Number is required. ASSIGNEE NAME A PLEASE NOTE: Un recordation as set for (A) NAME OF ASSI dease check the appropri- a. The following fee(s) Issue Fee Publication Fee (f) Advance Order - 4 . Change in Entity Sta Applicant certifyi Applicant changin TOTE: This form must b	IND RESIDENCE DATA less an assignee is identi h in 37 CFR 3.11. Comp GNEE riate assignee category or are submitted: No small entity discount p \$ of Copies	fied below, no assigne letion of this form is No categories (will not be ermitted) above) 2 37 CFR 1.29 37 CFR 1.29 37 CFR 1.29 if ee status.	e data will appear on the pa OT a substitute for filing an (B) RESIDENCE: (CITY printed on the patent) : 4b. Payment of Fee(s): (Plea A check is enclosed. Payment by credit car The director is hereby overpayment, to Depo <u>NOTE:</u> Absent a valid ce fee payment in the micro <u>NOTE:</u> If the application to be a notification of loss <u>NOTE:</u> Checking this boy entity status, as applicable 33. See 37 CFR 1.4 for signal	and STATE OR CO Individual Cor se first reapply any d. Form PTO-2038 i authorized to charge sit Account Number rtification of Micro I entity amount will n was previously unde s of entitlement to m s will be taken to be a.	DUNTRY)         poration or other private growth         y previously paid issue feet         s attached.         e the required fee(s), any defect	bup entity Governme shown above) Triciency, or credits any n extra copy of this form D/SB/15A and 15B), issu application abandonmer ing this box will be taken tlement to small or micro

Find authenticated court documents without watermarks at docketalarm.com.

	ted States Pate	NT AND TRADEMARK OFFICE	UNITED STATES DEPAR United States Patent and A Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 223 www.uspto.gov	<b>Frademark Office</b> OR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
14/958,259	12/03/2015	Bruce Scharschmidt	HOR0026-201TC2-US	3046
101325 75	90 03/08/2016		EXAM	IINER
GLOBAL PATE 1005 NORTH WA	NT GROUP - HOR RSON ROAD		RAO, SAV	VITHA M
SUITE 404			ART UNIT	PAPER NUMBER
SAINT LOUIS, M	O 63132		1621	
			DATE MAILED: 03/08/201	6

### **Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)**

(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

### OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

### **Privacy Act Statement**

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- 1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- 3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.

DOCKE

		Application No. 14/958,259	Applicant(s SCHARSCH	) IMIDT ET AL.
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously malled), a Notice of Allowance (PT-LeS) or other appropriate communication will be mailed in due course. NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the 1 of the Office or upon petition by the applicant. See 37 OFR 1.313 and MPEP 1308.  1.  This communication is responsive to <u>02/18/2016</u> .  A declaration(s)/affidavit(s) under 37 OFR 1.130(b) was/were filed on  3.  An election was made by the applicant in response to a restriction requirement set forth during the interview on; the rest requirement and election have been incorporated into this action. 3.  The allowed claim(s) is/are <u>22.24.282 and 36:45</u> . As a result of the allowed claim(s), you may be eligible to benefit from the 1 Prosecution Highway program at a participating intellectual property office for the corresponding application. For more inform please see http://www.uspto.cov/patents/int.events/coh/index.isp or send an inquiry to <u>PPH/seeback@uspto.gov/</u> . 4.  Certified copies of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). Certified copies of the priority documents have been received in Application No	Notice of Allowability	Examiner	Art Unit	AIA (First Inventor to File) Status
☐ A declaration(s)/affidavit(s) under 37 CFR 1.130(b) was/were filed on	All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT F	S (OR REMAINS) CLOSED 5) or other appropriate comm <b>RIGHTS.</b> This application is	in this application. If no nunication will be mailed	et included I in due course. <b>THIS</b>
<ul> <li>2. ☐ An election was made by the applicant in response to a restriction requirement set forth during the interview on; the restrequirement and election have been incorporated into this action.</li> <li>3. ☐ The allowed claim(s) <i>is/are <u>22-24, 28 - 29 and 36-45</u>. As a result of the allowed claim(s), you may be eligible to benefit from the 1 Prosecution Highway program at a participating intellectual property office for the corresponding application. For more inform please see <u>http://www.usplo.gov/acatents/nit.events/pol/index.isp</u> or send an inquiry to <u>PPHfeedback@usplo.gov</u>.</i></li> <li>4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). Certified copies: <ul> <li>a) ☐ All</li> <li>b) ☐ Some "c) ☐ None of the:</li> <li>1. ☐ Certified copies of the priority documents have been received.</li> <li>2. ☐ Certified copies of the priority documents have been received in Application No</li> <li>3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ul> </li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requiremen noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.</li> <li>5. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.</li> <li>☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date</li></ul>	1. X This communication is responsive to <u>02/18/2016</u> .			
requirement and election have been incorporated into this action.         3. ☑ The allowed claim(s) is/are 22-24.28.29 and 36-45. As a result of the allowed claim(s), you may be eligible to benefit from the 1 Prosecution Highway program at a participating intellectual property office for the corresponding application. For more inform please see http://www.uspto.gov/patents/init_events/pbt/index.isp or send an inquiry to PPHreedback@uspto.gov.         4. □ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).         Certified copies: <ul> <li>a) □ All b) □ Some *c) □ None of the:</li> <li>1. □ Certified copies of the priority documents have been received.</li> <li>2. □ Certified copies of the priority documents have been received in Application No</li> <li>3. □ Copies of the certified copies of the priority documents have been received in this national stage application from</li></ul>	A declaration(s)/affidavit(s) under <b>37 CFR 1.130(b)</b> wa	as/were filed on <u> </u>		
Prosecution Highway program at a participating intellectual property office for the corresponding application. For more inform please see http://www.uspto.gov/batents/init_events/pol/index.jsp or send an inquiry to PPH/feedback@uspto.gov.         4			h during the interview o	n; the restricti
Certified copies:         a) □ All b) □ Some *c) □ None of the:         1. □ Certified copies of the priority documents have been received.         2. □ Certified copies of the priority documents have been received in Application No         3. □ Copies of the certified copies of the priority documents have been received in this national stage application from International Bureau (PCT Rule 17.2(a)).         * Certified copies not received:         Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requiremen noted below. Failure to timely comply will result in ABANDONMENT of this application.         THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.         5. □ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.         □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date         Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).         6. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL.         Attachment(s)       5. □ Examiner's Amendment/Comment         1. □ Notice of References Cited (PTO-892)       5. □ Examiner's Amendment/Comment         2. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	Prosecution Highway program at a participating intellectu	ual property office for the cor	responding application.	For more information
<ul> <li>a)AIb)Some _*c)None of the: <ol> <li>Certified copies of the priority documents have been received.</li> <li>Certified copies of the priority documents have been received in Application No</li> <li>Copies of the certified copies of the priority documents have been received in this national stage application from International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> </ol></li></ul> Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirement noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5 CORRECTED DRAWINGS ( as "replacement sheets") must be submitted including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL. Attachment(s) 1 Notice of References Cited (PTO-892) 5 Examiner's Amendment/Comment 6 Examiner's Amendment/Comment 6 Examiner's Comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1 Notice of References Cited (PTO-892) 5 Examiner's Amendment/Comment 6 Examiner's Comment Regarding Requirement for Deposit 7 Other (SAVITHA RAO/	4. Acknowledgment is made of a claim for foreign priority und	der 35 U.S.C. § 119(a)-(d) ol	. (f).	
1. □ Certified copies of the priority documents have been received.     2. □ Certified copies of the priority documents have been received in Application No     3. □ Copies of the certified copies of the priority documents have been received in this national stage application from International Bureau (PCT Rule 17.2(a)).     * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requiremen noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. □ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.     □ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. □ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.  Attachment(s) 1. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 2. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 2. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 2. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 3. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 4. □ Interview Summary (PTO-413), Paper No./Mail Date 3. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 3. □ Interview Summary (PTO-413), Paper No./Mail Date 3. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material 4. □ Interview Summary (PTO-413), Paper No./Mail Date 3. □ Ex	Certified copies:			
Cortified copies of the priority documents have been received in Application No     Copies of the certified copies of the priority documents have been received in this national stage application from International Bureau (PCT Rule 17.2(a)).     * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requiremen noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.     including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).  Attachment(s)  DePOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the off References Cited (PTO-892)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the deposit of Deposit of BIOLOGICAL MATERIAL.  Attachment(s)  Deprove the d	a) 🔲 All b) 🗌 Some *c) 🔲 None of the:			
3Copies of the certified copies of the priority documents have been received in this national stage application from International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirement noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5 CORRECTED DRAWINGS ( as "replacement sheets") must be submitted including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6 DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1 Notice of References Cited (PTO-892) 5 Examiner's Amendment/Comment 4 Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date YSAVITHA RAO/				
International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requiremen noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.				
* Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirement noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted. including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. Notice of References Cited (PTO-892) 5. Examiner's Amendment/Comment 6. Examiner's Comment Regarding Requirement for Deposit of BIOLOgical Material 1. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date		locuments have been receive	ed in this national stage	application from the
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirement noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted. including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Attachment(s) 1. Notice of References Cited (PTO-892) 2. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 3. Examiner's Comment Regarding Requirement for Deposit of Biological Material 4. Interview Summary (PTO-413), Paper No./Mail Date /SAVITHA RAO/				
noted below. Failure to timely comply will result in ABANDONMENT of this application.         THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.         5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.         including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date         Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).         6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.         Attachment(s)       5. Examiner's Amendment/Comment         0. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	* Certified copies not received:			
<ul> <li>each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).</li> <li>6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> <li>Attachment(s) <ol> <li>Notice of References Cited (PTO-892)</li> <li>Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date</li></ol></li></ul>	5. CORRECTED DRAWINGS ( as "replacement sheets") mu including changes required by the attached Examine Paper No./Mail Date	r's Amendment / Comment o		
Attachment(s)          1. □ Notice of References Cited (PTO-892)       5. □ Examiner's Amendment/Comment         2. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date       6. ☑ Examiner's Statement of Reasons for Allowance         3. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material       7. □ Other         4. □ Interview Summary (PTO-413), Paper No./Mail Date       .         /SAVITHA RAO/       ////////////////////////////////////	each sheet. Replacement sheet(s) should be labeled as such in	the header according to 37 C	FR 1.121(d).	(not the back) of
<ul> <li>1. □ Notice of References Cited (PTO-892)</li> <li>2. □ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date3.</li> <li>3. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material</li> <li>4. □ Interview Summary (PTO-413), Paper No./Mail Date</li> <li>/SAVITHA RAO/</li> <li>5. □ Examiner's Amendment/Comment</li> <li>6. ⊠ Examiner's Statement of Reasons for Allowance</li> <li>7. □ Other</li> </ul>				the
<ul> <li>2. ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date3. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material</li> <li>4. ☐ Interview Summary (PTO-413), Paper No./Mail Date</li> <li>/SAVITHA RAO/</li> </ul>				
Paper No./Mail Date 3.  Examiner's Comment Regarding Requirement for Deposit of Biological Material 1.  Interview Summary (PTO-413), Paper No./Mail Date /SAVITHA RAO/				
B. □ Examiner's Comment Regarding Requirement for Deposit of Biological Material       7. □ Other         M. □ Interview Summary (PTO-413), Paper No./Mail Date       7. □ Other	Paper No./Mail Date	o. 🖂 Examiner	Statement of Reasons	SION ANOWANCE
4. □ Interview Summary (PTO-413), Paper No./Mail Date /SAVITHA RAO/		7. 🗌 Other		
	4. 🔲 Interview Summary (PTO-413),			
J.S. Patent and Trademark Office PTOL-37 (Rev. 08-13) Notice of Allowability Part of Paper No./Mail Date 20		otice of Allowability	Part of Pape	r No./Mail Date 20160

## DOCKET A L A R M



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

### LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

### FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

### E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.